Literature DB >> 2130296

Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients.

J R Boelaert1, B F Cantinieaux, C F Hariga, P G Fondu.   

Abstract

Iron overload increases the risk of bacterial infection in dialysis patients, partly by impairing functions of the polymorphonuclear granulocytes (PMNs). PMN defence was studied sequentially in haemodialysis patients with transfusional haemosiderosis, treated for 6 +/- 1.5 months (n = 8) to 13 +/- 1.7 months (n = 4) with recombinant human erythropoietin (rHuEpo). Over this period, signs of iron overload (increased serum ferritin and serum iron) improved, and stainable iron disappeared in PMNs. Simultaneously, phagocytosis of Yersinia enterocolitica by PMNs improved. The decrease in serum ferritin was significantly related to the improved phagocytosis. Killing of Y. enterocolitica by PMNs also improved. It is anticipated that rHuEpo therapy in iron-overloaded dialysis patients could decrease the incidence of bacterial infection by improving PMN functions in these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2130296     DOI: 10.1093/ndt/5.7.504

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

Review 1.  Safety aspects of parenteral iron in patients with end-stage renal disease.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

Review 2.  Iron and infection in hemodialysis patients.

Authors:  Julie H Ishida; Kirsten L Johansen
Journal:  Semin Dial       Date:  2013-12-12       Impact factor: 3.455

3.  Iron in granulocytes of nephrotic patients determined by Zeeman electrothermal atomic absorption spectrophotometry.

Authors:  M Matthys; V Blaton; J Spincemaille
Journal:  Biol Trace Elem Res       Date:  1992 Jan-Mar       Impact factor: 3.738

Review 4.  Hematologic aspects of end-stage renal failure.

Authors:  P Zachée; J Vermylen; M A Boogaerts
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

5.  Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

Authors:  F Silvestris; A Romito; P Fanelli; A Vacca; F Dammacco
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.